JNCCN 360

Editor:

Karl D. Lewis, MD

Advertisement

Advertisement

Nikolaos Andreatos, MD, on Adverse Events Following Radiotherapy and Immunotherapy in Patients With Melanoma and Merkel Cell Carcinoma

Danny Rischin, MD, on Cutaneous Squamous Cell Carcinoma: Follow-up Data on Cemiplimab

Michael K.K. Wong, MD, PhD, on KRT-232: First-in-Class Agent for Merkel Cell Carcinoma

Recent

AACR II: Linking HPV Infection to Skin Cancer in Patients With CLL

Immune-Mediated Adverse Events With Concomitant Radiotherapy and Immunotherapy

AACR II: Does Cyclooxygenase-2 Inhibitor Use Reduce the Risk of Skin Cancer?

AACR II: Early Tanning Bed Use and Risk for Skin Cancer

Published

Medical Literature

COVID-19 and Non-Melanoma Skin Cancer: Revisiting Hypofractionated Radiotherapy

Multiple Aggregated, Yellow-White Globules: Indicator of Basal Cell Carcinoma?

Non-Melanoma Skin Cancer and COVID-19: Modifications to Current Radiotherapy

Genetic Features of Virus-Positive Versus Virus-Negative Merkel Cell Carcinoma

Ongoing

The Role Of PD-1 Inhibitors in The Evolving Landscape of Advanced Cutaneous Squamous Cell Carcinoma Treatment

A Multidisciplinary Approach to Individualized Patient Care: Non-Melanoma Skin Cancer

No Elevated Cancer Risk for RA Patients With Tocilizumab

Could AI Trained to ID Skin Cancer Attain Accuracy of Dermatologists?

Available

Clinical Trials

MD Anderson Cancer Center

University of California San Diego Moores Cancer Center

Memorial Sloan Kettering Cancer Center

University of Nebraska

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.